BrightPath Biotherapeutics Co., Ltd. (4594.T)
JPY 40.0
(2.56%)
JPY 40.0
(2.56%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -341 Thousand JPY | -110.07% |
| 2022 | 3.38 Million JPY | -72.0% |
| 2021 | 12.09 Million JPY | 789.7% |
| 2020 | 1.35 Million JPY | -80.11% |
| 2019 | 6.83 Million JPY | -91.97% |
| 2018 | 85.1 Million JPY | 116.91% |
| 2017 | 39.23 Million JPY | 734.99% |
| 2016 | 4.69 Million JPY | -90.77% |
| 2015 | 50.89 Million JPY | -7.47% |
| 2014 | 55 Million JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 21 Thousand JPY | 125.61% |
| 2023 Q2 | 21 Thousand JPY | 75.0% |
| 2023 Q1 | 12 Thousand JPY | 102.14% |
| 2023 Q3 | 18 Thousand JPY | -14.29% |
| 2023 FY | -341 Thousand JPY | -110.07% |
| 2023 Q4 | -82 Thousand JPY | -555.56% |
| 2022 Q4 | -562 Thousand JPY | -114.74% |
| 2022 Q3 | 3.81 Million JPY | 6830.91% |
| 2022 FY | 3.38 Million JPY | -72.0% |
| 2022 Q2 | 55 Thousand JPY | -31.25% |
| 2022 Q1 | 80 Thousand JPY | -99.32% |
| 2021 Q3 | 50 Thousand JPY | 28.21% |
| 2021 Q1 | 159 Thousand JPY | -32.34% |
| 2021 Q4 | 11.84 Million JPY | 23586.0% |
| 2021 Q2 | 39 Thousand JPY | -75.47% |
| 2021 FY | 12.09 Million JPY | 789.7% |
| 2020 Q4 | 235 Thousand JPY | -26.1% |
| 2020 FY | 1.35 Million JPY | -80.11% |
| 2020 Q1 | 240 Thousand JPY | -95.19% |
| 2020 Q2 | 566 Thousand JPY | 135.83% |
| 2020 Q3 | 318 Thousand JPY | -43.82% |
| 2019 Q2 | 594 Thousand JPY | -3.88% |
| 2019 Q4 | 4.99 Million JPY | 692.22% |
| 2019 Q1 | 618 Thousand JPY | -2.22% |
| 2019 Q3 | 630 Thousand JPY | 6.06% |
| 2019 FY | 6.83 Million JPY | -91.97% |
| 2018 FY | 85.1 Million JPY | 116.91% |
| 2018 Q4 | 632 Thousand JPY | -92.8% |
| 2018 Q3 | 8.78 Million JPY | -44.41% |
| 2018 Q2 | 15.79 Million JPY | -73.63% |
| 2018 Q1 | 59.89 Million JPY | 83.4% |
| 2017 Q1 | 2.8 Million JPY | 175.79% |
| 2017 Q2 | 1.93 Million JPY | -30.84% |
| 2017 Q3 | 1.83 Million JPY | -5.26% |
| 2017 Q4 | 32.66 Million JPY | 1678.87% |
| 2017 FY | 39.23 Million JPY | 734.99% |
| 2016 FY | 4.69 Million JPY | -90.77% |
| 2016 Q3 | 4.27 Million JPY | 78.35% |
| 2016 Q2 | 2.39 Million JPY | 39.04% |
| 2016 Q1 | 1.72 Million JPY | -85.74% |
| 2016 Q4 | -3.69 Million JPY | -186.48% |
| 2015 FY | 50.89 Million JPY | -7.47% |
| 2015 Q4 | 12.08 Million JPY | 1.41% |
| 2015 Q3 | 11.91 Million JPY | -11.84% |
| 2015 Q1 | 13.37 Million JPY | 0.0% |
| 2015 Q2 | 13.51 Million JPY | 1.08% |
| 2014 FY | 55 Million JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.88 Billion JPY | 100.018% |
| PRISM BioLab Co.,LTD | 80.3 Million JPY | 100.425% |
| GNI Group Ltd. | 22.43 Billion JPY | 100.002% |
| Linical Co., Ltd. | 3.77 Billion JPY | 100.009% |
| Trans Genic Inc. | 2.24 Billion JPY | 100.015% |
| MEDINET Co., Ltd. | 98.25 Million JPY | 100.347% |
| Soiken Holdings Inc. | 2.48 Billion JPY | 100.014% |
| Cytori Cell Research Institute, Inc. | 1.29 Billion JPY | 100.026% |
| AnGes, Inc. | -3.06 Billion JPY | 99.989% |
| OncoTherapy Science, Inc. | -177.71 Million JPY | 99.808% |
| Nxera Pharma Co., Ltd. | 9.66 Billion JPY | 100.004% |
| Immuno-Biological Laboratories Co., Ltd. | 517.29 Million JPY | 100.066% |
| NanoCarrier Co., Ltd. | 110.95 Million JPY | 100.307% |
| Carna Biosciences, Inc. | 1.45 Billion JPY | 100.024% |
| CanBas Co., Ltd. | -984 Million JPY | 99.965% |
| D. Western Therapeutics Institute, Inc. | 391.69 Million JPY | 100.087% |
| RaQualia Pharma Inc. | 1.65 Billion JPY | 100.021% |
| Chiome Bioscience Inc. | 398.59 Million JPY | 100.086% |
| Kidswell Bio Corporation | 1.03 Billion JPY | 100.033% |
| PeptiDream Inc. | 17.21 Billion JPY | 100.002% |
| Oncolys BioPharma Inc. | 30.6 Million JPY | 101.114% |
| Ribomic Inc. | -10.5 Million JPY | 96.753% |
| SanBio Company Limited | -14.5 Million JPY | 97.649% |
| Healios K.K. | 108 Million JPY | 100.316% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -59.04 Million JPY | 99.422% |
| Delta-Fly Pharma, Inc. | -1.51 Million JPY | 77.447% |
| StemRIM | -44.34 Million JPY | 99.231% |
| CellSource Co., Ltd. | 3.18 Billion JPY | 100.011% |
| FunPep Company Limited | -680.28 Million JPY | 99.95% |
| Kringle Pharma, Inc. | 69.25 Million JPY | 100.492% |
| Stella Pharma Corporation | 217.29 Million JPY | 100.157% |
| TMS Co., Ltd. | -6.95 Million JPY | 95.094% |
| Noile-Immune Biotech Inc. | 314.56 Million JPY | 100.108% |
| Cuorips Inc. | 9.63 Million JPY | 103.541% |
| K Pharma,Inc. | 910 Million JPY | 100.037% |
| Takara Bio Inc. | 25.45 Billion JPY | 100.001% |
| ReproCELL Incorporated | 1.1 Billion JPY | 100.031% |
| PhoenixBio Co., Ltd. | 1.19 Billion JPY | 100.029% |
| StemCell Institute Inc. | 1.57 Billion JPY | 100.022% |
| Japan Tissue Engineering Co., Ltd. | 1.66 Billion JPY | 100.02% |
| CellSeed Inc. | 107.15 Million JPY | 100.318% |